BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly to $633 from $565 and keeps an Outperform rating on the shares. The Mounjaro outperformance paired with Novo SELECT data bolster the firm’s outlook for uptake in T2D, the analyst tells investors in a research note. While manufacturing remains constrained, the new RTP site and Trulicity autoinjector synergies with Mounjaro’s injector help Lilly prepare for mounting demand, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY: